Jan-14-21 03:11AM |
With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBarrons.com |
Jan-11-21 08:02AM |
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex PharmaceuticalsZacks |
Jan-08-21 09:01AM |
CRISPR Gene Editing Stocks Up After Intellia's Pipeline UpdateZacks |
Jan-07-21 04:24AM |
Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily |
02:33AM |
Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily |
Jan-07-21 01:05AM |
Why Intellia Therapeutics Stock Is Soaring TodayMotley Fool |
08:42AM |
3 Biotech Technological Developments to Watch Out For in 2021Zacks |
Jan-07-21 07:30AM |
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021GlobeNewswire |
Jan-06-21 11:00AM |
A New Gene-Editing Technique May Be Able to Help Children Who Prematurely AgeBarrons.com |
Jan-04-21 09:27AM |
5 Disruptive Biotech Stocks With Solid Long-Term PotentialZacks |
Jan-01-21 01:22AM |
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Could Be 41% Below Their Intrinsic Value EstimateSimply Wall St. |
Dec-30-20 10:42AM |
The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana TherapeuticsZacks |
Dec-29-20 12:27PM |
Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayMotley Fool |
09:37AM |
5 Biotech Stocks That Have Gained More Than 200% in 2020Zacks |
Dec-21-20 04:24AM |
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily |
12:43PM |
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily |
Dec-16-20 09:33AM |
Is NTLA A Good Stock To Buy Now?Insider Monkey |
Dec-12-20 09:00AM |
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT DeficiencyGlobeNewswire |
Dec-10-20 02:03AM |
CRISPR Gene Editing: Owning the Future of MedicineZacks |
Dec-09-20 11:06AM |
Gene-Editing Stocks Skyrocket in $1.6 Billion Boom After DataBloomberg |
Dec-07-20 04:20AM |
Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily |
11:58AM |
Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily |
Dec-07-20 10:06AM |
Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily |
Dec-05-20 10:00AM |
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual MeetingGlobeNewswire |
Dec-04-20 04:01AM |
Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire |
08:00AM |
New Results on Blood Disorder Treatments Are Coming. Watch These Stocks.Barrons.com |
Dec-03-20 08:41AM |
Intellia (NTLA) Catches Eye: Stock Jumps 7.8%Zacks |
Dec-01-20 09:30AM |
Intellia Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire |
Nov-30-20 04:01AM |
Intellia Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire |
Nov-11-20 07:30AM |
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease TreatmentsGlobeNewswire |
Nov-09-20 07:30AM |
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin AmyloidosisGlobeNewswire |
05:57AM |
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest ResultsSimply Wall St. |
Nov-06-20 05:30AM |
Intellia Therapeutics, Inc. (NTLA) Q3 2020 Earnings Call TranscriptMotley Fool |
Nov-05-20 07:30AM |
Intellia Therapeutics Announces Third Quarter 2020 Financial ResultsGlobeNewswire |
06:15AM |
Intellia Therapeutics, Inc. to Host Earnings CallACCESSWIRE |
Oct-29-20 07:30AM |
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company UpdatesGlobeNewswire |
Oct-27-20 10:35AM |
Benzinga's Top Upgrades, Downgrades For October 27, 2020Benzinga |
Oct-19-20 07:30AM |
Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)GlobeNewswire |
Oct-07-20 04:20AM |
Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing TechnologyGlobeNewswire |
10:04AM |
Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other StocksBarrons.com |
Oct-05-20 07:30AM |
Intellia Therapeutics Names John F. Crowley to Board of DirectorsGlobeNewswire |
Sep-29-20 08:20AM |
Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based TreatmentGlobeNewswire |
Sep-28-20 08:00AM |
Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines ConferenceGlobeNewswire |
Sep-22-20 09:43AM |
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%TipRanks |
Sep-18-20 09:31AM |
Benzinga's Top Upgrades, Downgrades For September 18, 2020Benzinga |
Sep-02-20 08:00AM |
Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare ConferenceGlobeNewswire |
Aug-11-20 11:10AM |
We're Not Worried About Intellia Therapeutics' (NASDAQ:NTLA) Cash BurnSimply Wall St. |
11:06AM |
How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own?Simply Wall St. |
Aug-06-20 09:15AM |
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue EstimatesZacks |
07:30AM |
Intellia Therapeutics Announces Second Quarter 2020 Financial ResultsGlobeNewswire |